论文部分内容阅读
近年来儿童急性淋巴细胞白血病(ALL)的预后已有明显的改善,但是复发后即便是应用更强的化疗方案,长期无病存活率(DFS)一般在10％～30％以下。本研究对儿童ALL在CR2或CR3复发后改用全身放疗、大剂量化疗联合同胞匹配异基因骨髓移植(ABMT)进行治疗,结果如下。 病人与方法 病人共116例,中位年龄9.4岁(2～18),男77例,女39例。CR1的中位时间为18.5个月。骨髓复发85例,其中混合性复发25例,中枢神经系统(CNS)复发31例。92例在CR2进行同胞ABMT,10例CR3,14例在CR2复发期间移
The prognosis of childhood acute lymphoblastic leukemia (ALL) has been significantly improved in recent years. However, the long-term disease-free survival (DFS) is generally below 10% to 30% even after more advanced chemotherapy regimens. This study of children ALL after CR2 or CR3 relapse after the switch to systemic radiotherapy, high-dose chemotherapy combined with sibling allogeneic bone marrow transplantation (ABMT) for treatment, the results are as follows. Patients and Methods A total of 116 patients with a median age of 9.4 years (2 ~ 18), 77 males and 39 females. The median time to CR1 was 18.5 months. There were 85 cases of bone marrow recurrence, including 25 cases of mixed recurrence and 31 cases of central nervous system (CNS) recurrence. 92 cases of sibling ABMT in CR2, 10 cases of CR3, 14 cases during CR2 recurrence